36725-30-1

Upstream product

• 1205-36-3 2-bromo-1-(3-nitrophenyl)propan-1-one 
• 17408-16-1 3'-nitropropiophenone 
• 42075-28-5 3-m-nitrobenzoyl butyric acid 

Downstream Products

• 67820-89-7 N'-[5-methyl-6-(3-nitro-phenyl)-pyridazin-3-yl]-hydrazinecarboxylic acid tert-butyl ester 
• 66548-48-9 3-chloro-5-methyl-6-(m-nitrophenyl)-pyridazine 
• 36725-31-2 6-(3-aminophenyl)-5-methyl-4,5-dihydro-2H-pyridazin-3-one 

Relevant academic research and scientific papers

Synthesis and structure-activity relationships of cis-tetrahydrophthalazinone/pyridazinone hybrids: A novel series of potent dual PDE3/PDE4 inhibitory agents

In this study, the synthesis and in vitro and in vivo pharmacological investigations of a new series of phthalazinone/pyridazinone hybrids with both PDE3 and PDE4 inhibitory activities are described. These compounds combine the pharmacophores of recently discovered 4a,5,8,-8a-tetrahydro-2H-phthalazin-1-one-type inhibitors of PDE4 and the well-known 2H-pyridazin-3-one-type PDE3 inhibitors such as the tetrahydrobenzimidazoles. Most of the synthesized compounds are pharmacologically spoken PDE3/PDE4 hybrids. All hybrids show potent PDE4 inhibitory activity (pIC50 = 7.0-8.7), whereas the pIC50 values for inhibition of PDE3 vary from 5.4 to 7.5. In general, analogues with a 5-methyl-4,5-dihydropyridazinone moiety exhibit the highest PDE3 inhibitory activities. The highest in vivo antiinflammatory activity is displayed by phthalazinones 43 and 44 showing, at a dose of 30μmol/kg po, 46% inhibition of arachidonic acid (AA) induced mouse ear edema. No correlation was found between the in vitro PDE3 and/or PDE4 inhibitory activity and the in vivo antiinflammatory capacity after oral dosing.

Method for treating anxiety in mammals

This disclosure describes compositions of matter useful as anxiolytic agents and the method of meliorating anxiety in mammals therewith; the active ingredients of said compositions of matter being certain substituted 6-phenyl-1,2,4-triazolo[4,3-b]pyridazines or the pharmacologically acceptable acid-addition salts thereof.

6-Phenyl-1,2,4-triazolo[4,3-b]pyridazine hypotensive agents

This disclosure describes novel substituted 6-phenyl-1,2,4-triazolo[4,3-b]pyridazines useful as hypotensive agents.